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The introduction of non-vitamin K antagonists oral anticoagulants, a class of medicines which 
includes dabigatran, apixaban, edoxaban and rivaroxaban, has resulted in improvements in the 
safety and efficacy of non valvular atrial fibrillation treatment for stroke prevention, with sig-
nificant reductions in stroke, intracranial haemorrhage, and mortality. For these reasons, a team 
of World Heart Federation Emerging Leaders led efforts to add non-vitamin K antagonists oral 
anticoagulants to the World Health Organization’s Model List of Essential Medicines in 2019. 
Following the inclusion of this class of medicines in the Essential Medicines List, this editorial 
proposes several recommendations to improve the accessibility, affordability and acceptability 
of non-vitamin K oral anticoagulants, especially in low- and middle-income settings, in order to 
successfully manage non-valvular atrial fibrillation and to lower the risk of stroke.
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This editorial aims to inform policy development to increase the availability, affordability and acceptability 
of non-vitamin K antagonists oral anticoagulant (NOACs), for instance by adding NOACs into the National 
Essential Medicines lists, following the addition of this class of medicines to WHO Model List of Essential 
Medicines (EML). It includes the perspectives of several key constituencies, including academia, policy and 
advocacy, and the World Heart Federation’s leadership, and considers relevant COVID-19 developments for 
NOACs and cardiovascular health.  
Atrial fibrillation (AF) is associated with a higher risk of hospital admissions, cerebrovascular and cardio-
vascular conditions, and premature death. Over 37.5 million people are affected by AF [1], with 58% of those 
suffering from it aged 70 years and over. Current projections suggest an expected increase in the incidence 
and prevalence in the next three decades due to population growth, ageing, and better survival among 
patients with AF [2–4]. By 2020, an estimated 17.9 million people in low- and middle-income countries 
(LMICs) will be living with nonvalvular atrial fibrillation (NVAF) [5]. Many of those affected by AF in LMICs 
are, less likely to access preventive measures and to receive a timely diagnosis (e.g., lack of access to ECG) and 
the anti-coagulation treatment they require as per AF management guidelines (see Table 1), which leads to 
significant health and economic burden [6–8]. 
Vitamin K Antagonist (VKAs) oral anticoagulants are effective in preventing AF-related strokes [9]; how-
ever, patients treated with VKAs must be carefully monitored to effectively reduce the risk of embolic stroke 
while minimizing bleeding risks. In fact, factors like illness, consumption of vitamin K-rich foods, alcohol, 
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and medications can interfere with patients’ ability to stay within the therapeutic range. Furthermore, the 
regular monitoring required for VKA treatment is particularly challenging for patients and health systems, 
especially in remote and resource-limited settings where health systems are often poorly equipped to care 
for people affected by AF. This regular monitoring can be even more challenging during public health cri-
ses such as the COVID-19 pandemic, which led to a decrease in the volume of cardiology visits around the 
world [10–12].
In the past ten years, the introduction of NOACs, a class of medicines which includes dabigatran, apixaban, 
edoxaban and rivaroxaban [13], has resulted in improvements in the safety and efficacy of NVAF treatment 
for stroke prevention, with significant reductions in stroke, intracranial haemorrhage, and mortality [14]. 
The advantage of NOACs over VKAs is that patients on NOACs do not require routine monitoring and are not 
subject to the same treatment interference challenges such as the risk of bleeding, drug-drug interactions, 
dietary restrictions. Accordingly, major clinical practice guidelines worldwide recommend NOACs over VKAs 
for initial treatment of NVAF for stroke prevention [14]. Unfortunately, NOACs are less available and afford-
able in LMICs where they are most needed [15]. 
For these reasons, a team of World Heart Federation Emerging Leaders led efforts to add NOACs to 
the WHO Model List of Essential Medicines (EML). The team involves experts in cardiology, neurology 
and public health from ten countries which concluded, in their successful appeal to WHO, that NOACs 
were not only safer (lower risk of major bleeding) and more effective, but also more cost-effective than 
VKAs in preventing stroke and systemic embolism in NVAF patients [14]. These conclusions were based on 
findings from pivotal randomized controlled trials [16–19] and large-scale, real-world registries [20–22]. 
This new application overcame the limitations of a previous attempt [23] to add NOACS to the EML which 
was rejected for several reasons, including the belief that evidence based only on trial populations would 
not be representative of patients who would receive such treatment in real-world practice, the lack of 
specific antidotes at the time to reverse anti-coagulation, and the higher costs compared to warfarin and 
to the overall benefits to patients [24–26].
The designation as an essential medicine by the WHO signifies the therapeutic value and importance of 
NOACs. The WHO EML listing is meant to lead to a cascade of actions that will improve equitable access 
to essential medicines, considering that many governments utilize the WHO EML as a model for setting 
their own medicine priorities [27]. Bringing NOACs within reach of those who need them most, especially 
in low- and middle-income countries, is the next frontier in ensuring access to anti-coagulation therapy, 
successfully managing NVAF and lowering the risk of stroke. To achieve this, we recommend the following 
policy actions.
Table 1: Treatment guidelines by stroke risk stratification for patients with AF.
Low stroke risk 
(CHADSVASC = 0)
Moderate stroke risk 
(CHADSVASC = 1)
High stroke risk (CHADSVASC ≥ 2)
AHA/ACC No anticoagulants OACs or aspirin (LOE IIb) NOACs (dabigatran, rivaroxaban, apixaban, and 
edoxaban) are recommended over warfarin (IA)





NOAC (IA)c, VKA (IA)c,d
NICE No antithrombotic 
therapy
Consider OAC (Warfarin 
or NOACs Apixaban, 
Dabigatran, Rivaroxaban)
Offer OAC (Warfarin or NOACs Apixaban, 
Dabigatran, Rivaroxaban)
ASIA PACIFIC No anticoagulants OACs NOACs preferred to warfarin
CANADA No antithrombotic 
therapy
OAC or Aspirin NOACs
AUSTRALIA No anticoagulants OACs (GRADE: Strong; 
Evidence:
Moderate).
Warfarin, NOAC (apixaban, dabigatran or 
rivaroxaban) (GRADE: Strong; Evidence:High.)
ARGENTINA No anticoagulants OACs or aspirin (LOE I B) OAC (IA) with Warfarin or NOACs
MEXICO Dabigatran or Warfarin (Recommended 2011)
BRAZIL No anticoagulants OAC (LOE IIaC) OAC (IA) with Warfarin or NOACs
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Inclusion of NOACs within Key Health Systems Policies 
Making quality NOACs available, affordable, acceptable and accessible in-country will often require govern-
ments to include them in their national essential medicines list, clinical treatment guidelines, and other 
policy tools that ensure their supply and provision in health facilities and pharmacies. 
According to data from 2017, 14 countries, primarily in the WHO Europe Region, had listed dabigatran on 
their national essential medicines lists prior to the WHO recommendation and a subset of those countries 
also listed apixaban and/or rivaroxaban [28]. This number has already and is expected to further increase 
after the WHO listing, as medicines listed by WHO tend to be included by a greater number of national 
EMLs over time, especially in lower-middle and low-income countries [28]. While medicines listed on 
national EMLs generally become more available and affordable than other medicines, a multitude of diverse 
factors likely affect priority-setting for national EMLs and various policy and health system barriers must 
be overcome to ensure equitable access to essential medicines [29, 30]. For example, pricing of medicines 
influences EML inclusion; low-income countries with poor government control on prices appear to be less 
likely to adopt the WHO EML if the drug prices are deemed too high [31]. 
Work is also required to increase the acceptability of NOACs, for example, by including it in national guide-
lines for the management of NVAF and in training packages for healthcare providers. Alignment of policies 
such as clinical treatment guidelines and EMLs at national and subnational levels can reduce unnecessary 
policy barriers to care.
Improving Affordability
In the case of NOACs, the cost is likely one important barrier. Although it is deemed cost-effective, all four 
NOACs—dabigatran, rivaroxaban, apixaban and edoxaban—remain patent protected in several countries,1 
and their cost can vary widely. This variation in cost can hinder availability and make NOACs prohibitive in 
some low-income settings. For example, dabigatran costs USD$65 in the UK and USD$222 in China and 
rivaroxaban costs approximately USD$60 per patient per month in Kenya [14, 32]. Yet factoring in costs 
associated with VKAs treatment — medication (available at a price as low as USD$1 per month) and health 
care system costs, such as monitoring requirements — suggests that NOACs are expected to have a lower 
cost over time [32]. 
We can learn from actions that have resulted in improvements in global access to expensive, patented HIV 
and hepatitis C treatments, following their additions to the WHO EML in 2001 and 2015, respectively. These 
actions include the promotion of generic competition, voluntary licensing of products such as through the 
Medicines Patent Pool (MPP), and invoking flexibilities enshrined in the World Trade Organization’s Trade 
Related Aspects of Intellectual Property Rights (TRIPS) agreement [33, 34]. MPP reported that generic ver-
sions of dabigatran currently exist on the Indian private market, priced as low as between USD$15 and 
USD$22 per month (the recommended dose of dabigatran is 150 mg twice a day).2 Cost of production mod-
elling further indicated that NOACs could be produced at even lower costs, and thus it is expected that with 
greater volumes and market shares, it could be made available at lower prices while maintaining profitability 
[32]. Moving forward, it is estimated that licensing NOACs to MPP could allow generic entry years before pat-
ent expiry in a large number of LMICs and thereby “facilitate up to [an additional] 1.9 million patient-years 
of treatment for both nonvalvular atrial fibrillation and venous thromboelism [32].”
In order for NOACs to be affordable to households, governments should consider including them in health 
insurance packages and other financial schemes, in addition to efforts to lower costs already discussed. 
Taken together, these solutions have the potential to accelerate more equitable global access to care and 
essential medicines for people affected by NVAF and at risk of stroke who may otherwise not benefit from anti-
coagulation therapy because of the high monitoring costs of VKAs and the lifestyle challenges of remaining 
 1 According to https://www.medspal.org/, as of August 2020, there were patents pending or granted on the dabigatran 
compound or its salt form in Argentina, Belarus,  Brazil, Chile, China, Colombia, Egypt, India, Indonesia, Kazakhstan, Kyrgyzstan, 
Malaysia, Mexico, Montenegro, Pakistan, Peru, Philippines, Russian Federation, Serbia, South Africa, Thailand, Turkey, Ukraine, 
Uzbekistan, Venezuela and Vietnam. There were patents pending or granted on apixaban in Albania, Argentina,  Brazil, Chile, 
China, Georgia, India, Indonesia, Kosovo, Kyrgyz Republic, Malaysia, Mexico, Montenegro, North Macedonia, Pakistan, Philippines, 
Russian Federation, Serbia, South Africa, Thailand, Turkey, Ukraine, Venezuela and Vietnam. Rivaroxaban had patents pending 
or granted in Albania, Argentina, Belarus, Bosnia and Herzegovina, Brazil, Chile, China, Colombia, Cuba, Dominican Republic, El 
Salvador, Guatemala, Honduras, India, Indonesia, Jamaica, Mexico, Morocco, North Macedonia, Pakistan, Peru, Philippines, Russian 
Federation, Serbia, South Africa, Trinidad and Tobago, Turkey,  Ukraine, Uruguay and Venezuela. Edoxaban had patents pending 
or granted in Argentina, Brazil, China, Egypt, India, Indonesia, Malaysia, Mexico, Pakistan, Philippines, Russian Federation, South 
Africa, Thailand, Turkey and Vietnam.
 2 The price is as found on www.1mg.com for Dabipla/Goodflo (150mg twice per day for 30 days).
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within the therapeutic range. These solutions are also in line with the World Heart Federation’s policy recom-
mendations on ensuring access to medicines for circulatory diseases, including strengthening health systems, 
designing and implementing creative financing models and investing in the health workforce [35]. 
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